Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New president for Sandoz's US operations

This article was originally published in Scrip

Executive Summary

Sandoz, the generics arm of Novartis, has named Don DeGolyer president of US operations and head of commercial operations for North America, effective April 1st. He will also become a member of Sandoz's executive committee. Mr DeGolyer was most recently senior vice-president and head of US commercial operations for Sandoz US. Before, he was senior vice-president of US managed markets & established medicines for Novartis Pharmaceuticals, the US affiliate of Novartis. Mr DeGolyer has also worked at Pfizer, Johnson & Johnson and Oxford GlycoSciences. Sandoz has also appointed Richard Tremonte vice-president of US retail sales and marketing, having previously served as senior director of marketing for Sandoz US, after joining in 2007. Mr Tremonte has worked in the generics industry for most of the past ten years, including more than five years at Teva Pharmaceuticals in various marketing and supply chain positions.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC007300

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel